Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
526.4 CHF | +3.87% | +0.04% | +48.83% |
Apr. 18 | Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... | |
Apr. 18 | Lonza Finance Launches EUR1 Billion 12-Year Euro Bond | DJ |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.98 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+48.83% | 40.08B | A | ||
+1.84% | 42.11B | B | ||
+7.51% | 40B | B- | ||
-10.82% | 26.87B | C | ||
+7.68% | 24.58B | B- | ||
-23.19% | 18.44B | B | ||
+2.55% | 11.94B | C+ | ||
+30.02% | 11.66B | C+ | ||
+7.27% | 11.01B | B+ | ||
-17.02% | 9.87B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LONN Stock
- Ratings Lonza Group AG